ADMA Biologics, Inc. (ADMA) Q3 2026 earnings results
ADMA Biologics, Inc. (ADMA) reported Q3 2026 results on Nov 4, 2026, 4:10:41 PM ET: GAAP EPS $0.22 vs. $0.20 expected (beat by 11.9%); revenue $141.10M vs. $138.12M expected (beat by 2.2%). Outlook: FY2026 total revenue expected to be at least $530 million.
| Metric | Reported | Analyst estimate | Result |
|---|---|---|---|
| EPS (GAAP, diluted) | $0.22 | $0.20 | Beat by 11.9% |
| Revenue | $141.10M | $138.12M | Beat by 2.2% |
Analyst estimate: the average forecast before the release.
Source
Figures from the SEC 8-K filing, released Nov 4, 2026, 4:10:41 PM ET. Nexqual published them 2 min 29 s after release. Each figure is confirmed by two independent extraction methods before it is published.
Year over year
Compared with the same quarter a year earlier (ended September 30, 2025, from the company's SEC filing): revenue grew 5.1% from $134.22M; GAAP diluted EPS was $0.22 vs. $0.15 (+46.7%).
Stock reaction
The results came out after the market closed. ADMA closed at $13.21 on November 5, 2026, up 26.0% from its $10.48 close on November 4, 2026 before the results. Latest: $12.70 as of 11:46 AM ET, +21.2% since the pre-release close.
Questions and answers
Did ADMA Biologics, Inc. beat earnings expectations?
Yes. ADMA Biologics, Inc. reported GAAP EPS of $0.22 against an average analyst estimate of $0.20 (beat by 11.9%), and revenue of $141.10M against $138.12M expected (beat by 2.2%).
What were ADMA Biologics, Inc.'s Q3 2026 earnings and revenue?
GAAP diluted EPS of $0.22 and revenue of $141.10M. Compared with the same quarter a year earlier (ended September 30, 2025, from the company's SEC filing): revenue grew 5.1% from $134.22M; GAAP diluted EPS was $0.22 vs. $0.15 (+46.7%).
When did ADMA Biologics, Inc. report Q3 2026 earnings?
Nov 4, 2026, 4:10:41 PM ET, in an SEC 8-K filing (Item 2.02).
How did ADMA stock react to the earnings?
The results came out after the market closed. ADMA closed at $13.21 on November 5, 2026, up 26.0% from its $10.48 close on November 4, 2026 before the results. Latest: $12.70 as of 11:46 AM ET, +21.2% since the pre-release close.
What did ADMA Biologics, Inc. say about its outlook?
FY2026 total revenue expected to be at least $530 million.
More on ADMA
ADMA stock page: price, SEC financials, insider trades, superinvestor holders, analyst estimates and options. All results reported that day: earnings November 4, 2026.
Source: SEC EDGAR 8-K (Item 2.02), Nexqual Earnings Flash. Built November 10, 2026 at 16:46 UTC. Not investment advice.
Data source: Nexqual. Last updated: November 10, 2026 at 16:46 UTC. This page is informational and not investment advice.
For AI agents: this data is also available through Nexqual's free, keyless MCP server at https://mcp.nexqual.com/mcp; every result includes source_url, as_of and cite_as. More: nexqual.com/agents · llms.txt